Ezetimibe · Zetia

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Mixed Hyperlipidemia, Homozygous Familial Hypercholesterolemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also in development:Atherosclerotic Cardiovascular Disease · Phase 3

Also approved (2)
US
  • ZETIA ® is indicated: in combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH); in combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH; in combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia; in combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH); as an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia. When ZETIA is used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use.
    FDA label
  • As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemiaOutside this platform's coverageFDA label
Product first approved 2002

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (73)
Atherosclerotic Cardiovascular Disease
NCT05970679 · Daewon Pharmaceutical Co., Ltd.
2022-08-17 – 2023-04-13 · Hypercholesterolemia, Dyslipidemia
What this study did
NCT03510884 · Sanofi
2018-05-31 – 2022-08-05 · Hypercholesterolaemia
What this study did
NCT02748057 · Organon and Co
2016-05-18 – 2017-12-11 · Hypercholesterolemia, Familial Hypercholesterolemia
What this study did
NCT02741245 · Organon and Co
2016-06-09 – 2017-01-18 · Hypercholesterolemia
What this study did
NCT02550288 · Organon and Co
2015-09-29 – 2016-05-30 · Hypercholesterolemia
What this study did
NCT02451098 · Chong Kun Dang Pharmaceutical
2015-03 – 2016-01 · Hyperlipidemia
What this study did
NCT03288038 · Shin Poong Pharmaceutical Co. Ltd.
2014-10-13 – 2015-11-19 · Hypercholesterolemia
What this study did
NCT01154036 · Organon and Co
2010-07 – 2012-10 · Hypercholesterolemia
What this study did
NCT00965055 · University of California, San Diego
2009-09 – 2012-09 · High Cholesterol, Coronary Artery Disease
What this study did
NCT02205775 · G. d'Annunzio University
2010-05 – 2012-06 · Stable Coronary Artery Disease Undergoing PCI
What this study did
NCT00867165 · Organon and Co
2009-05-21 – 2012-04-13 · Primary Hypercholesterolemia
What this study did
NCT00664469 · Sunnybrook Health Sciences Centre
2007-08 – 2010-11 · Hypercholesterolemia
What this study did
NCT00783263 · Organon and Co
2008-11 – 2010-05 · Hypercholesterolemia
What this study did
NCT00654095 · Organon and Co
2007-12-01 – 2009-06-01 · Hypercholesterolemia
What this study did
NCT00639158 · Abbott
2008-02 – 2008-10 · Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
What this study did
NCT00418834 · Organon and Co
2007-01 – 2008-10 · Hypercholesterolemia
What this study did
NCT00525824 · AstraZeneca
2007-08 – 2008-09 · Hypercholesterolemia, Coronary Heart Disease, Atherosclerosis
What this study did
NCT00276484 · Organon and Co
2006-02 – 2008-03 · Hypercholesterolemia
What this study did
NCT00195793 · Abbott
started 2004-08 · Hyperlipidemia
What this study did
NCT00552097 · Organon and Co
2002-06-01 – 2006-04-25 · Atherosclerosis, Hypercholesterolemia, Hyperlipoproteinemia Type II
What this study did
NCT00651560 · Organon and Co
2005-11-01 – 2005-12-23 · Hyperlipidemia
What this study did
NCT00110435 · Organon and Co
2005-05 – 2005-12 · Type 2 Diabetes Mellitus, Hypercholesterolemia
What this study did
NCT00395473 · Organon and Co
2005-03 – 2005-11 · Hypercholesterolemia
What this study did
NCT00457275 · Organon and Co
2005-04 – 2005-11 · Hypercholesterolemia
What this study did
NCT00093899 · Organon and Co
2004-11 – 2005-09 · Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia
What this study did
NCT00171288 · Novartis
2003-08 – 2005-08 · Dyslipidemia
What this study did
NCT00653445 · AstraZeneca
2004-06 – 2005-06 · Hypercholesterolemia, Coronary Heart Disease, Atherosclerosis
What this study did
NCT00092833 · Organon and Co
2002-07 – 2005-05 · Hypercholesterolemia, Familial, Lipid Metabolism, Inborn Errors
What this study did
NCT00650689 · Organon and Co
2003-05 – 2004-12 · Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease
What this study did
NCT00651404 · Organon and Co
2004-01 – 2004-12 · Hypercholesterolemia, Atherosclerosis
What this study did
NCT00090298 · Organon and Co
2004-04 – 2004-12 · Hypercholesterolemia
What this study did
NCT00090168 · Organon and Co
2004-01-27 – 2004-11-10 · Hypercholesterolemia, Atherosclerotic Disease, Coronary Disease
What this study did
NCT00092573 · Organon and Co
2003-04 – 2004-11 · Hypercholesterolemia, Hypertriglyceridemia
What this study did
NCT00651391 · Organon and Co
2003-10-01 – 2004-09-01 · Hypercholesterolemia, Atherosclerosis
What this study did
NCT00092625 · Organon and Co
2003-03 – 2004-08 · Hypercholesterolemia, Coronary Disease
What this study did
NCT00092638 · Organon and Co
2003-05 – 2004-08 · Hypercholesterolemia, Coronary Disease
What this study did
NCT00092599 · Organon and Co
2003-02 – 2004-07 · Hypercholesterolemia, Coronary Disease
What this study did
NCT00092612 · Organon and Co
2003-05 – 2004-06 · Hypercholesterolemia, Coronary Disease
What this study did
NCT00092690 · Organon and Co
2003-06 – 2004-03 · Hypercholesterolemia
What this study did
NCT00157911 · Organon and Co
2002-12 – 2003-12 · Hypercholerolemia
What this study did
NCT00092560 · Organon and Co
2002-12 – 2003-12 · Hypercholesterolemia, Hypertriglyceridemia
What this study did
NCT00092664 · Organon and Co
2003-01 – 2003-09 · Hypercholesterolemia
What this study did
Phase 2/3 (1)
Atherosclerotic Cardiovascular Disease
NCT02089867 · Jose Rocha Faria Neto
2006-10 – 2008-01 · Coronary Artery Disease
What this study did
Phase 2 (19)
Atherosclerotic Cardiovascular Disease
NCT07307989 · Chang Gung Memorial Hospital
2025-08-01 – 2029-07-31 · Ischemic Stroke, Hypercholesteremia
What this study did
NCT04173403 · Akeso
2019-11-04 – 2023-02-17 · Hypercholesterolemia
What this study did
NCT04770389 · NewAmsterdam Pharma
2021-02-23 – 2021-06-30 · Dyslipidemias, High Cholesterol, Hypercholesterolemia
What this study did
NCT03051100 · Esperion Therapeutics, Inc.
2017-01-19 – 2017-07-05 · Hypercholesterolemia
What this study did
NCT02055976 · Pfizer
2014-03 – 2015-01 · Hypercholesterolemia
What this study did
NCT01218204 · GlaxoSmithKline
2010-09-14 – 2011-06-29 · Dyslipidaemias, Dyslipidemias
What this study did
NCT00559962 · Aegerion Pharmaceuticals, Inc.
2007-10 – 2008-11 · Hyperlipidemia
What this study did
NCT00677248 · Karo Bio AB
2008-04 – 2008-10 · Hypercholesterolemia
What this study did
NCT00405067 · Aegerion Pharmaceuticals, Inc.
2006-05 – 2007-01 · Hypercholesterolemia
What this study did
NCT00157482 · Mario Negri Institute for Pharmacological Research
2005-01 – 2006-12 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT06437574 · Cedars-Sinai Medical Center
2024-07-16 – 2028-05-31 · Prostate Cancer
What this study did
NCT02971033 · VA Office of Research and Development
2018-04-16 – 2021-03-31 · Chronic Hepatitis C
What this study did
NCT03099278 · Ziauddin Hospital
2017-01 – 2017-10 · Chronic Hepatitis D
What this study did
NCT03105310 · Aga Khan University
2016-01 – 2017-06 · Hepatitis D, Chronic
What this study did
NCT02244944 · Gregory Graf, PhD
2014-09 – 2015-09 · Nonalcoholic Fatty Liver Disease (NAFLD)
What this study did
NCT01766713 · University of California, San Diego
2013-01 – 2014-09 · Non Alcoholic Steatohepatitis
What this study did
NCT00359281 · Aegerion Pharmaceuticals, Inc.
2006-03 – 2007-11 · Healthy
What this study did
NCT00045812 · National Heart, Lung, and Blood Institute (NHLBI)
2001-03 – 2004-04 · Lipoidosis
What this study did
Phase 1 (29)
Atherosclerotic Cardiovascular Disease
NCT05681247 · The Affiliated Hospital of Qingdao University
2017-12-17 – 2018-03-07 · Hyperlipidemias
What this study did
NCT01603758 · Richard E. Ostlund Jr., MD
2014-01 – 2015-06 · Coronary Heart Disease, Cardiovascular Disease, Dyslipidemia, Disorder of Cholesterol Metabolism
What this study did
NCT01723735 · Sanofi
2012-11 – 2013-07 · Hypercholesterolemia
What this study did
NCT01236430 · Organon and Co
2011-02 – 2012-02 · Hyperlipidemia
What this study did
NCT01597700 · GlaxoSmithKline
2012-01-13 – 2012-01-30 · Hypercholesterolaemia
What this study did
NCT00863265 · Washington University School of Medicine
2009-06 – 2010-02 · Hypercholesterolemia, Coronary Heart Disease
What this study did
NCT00653913 · Organon and Co
2004-03 – 2004-09 · Hypercholesterolemia
What this study did
NCT00651144 · Organon and Co
2003-03 – 2003-05 · Hypercholesterolemia, Atherosclerosis
What this study did
Other / comorbidity
NCT07235189 · Daiichi Sankyo
2025-10-28 – 2026-01-28 · Healthy Subjects
What this study did
NCT07182383 · Daiichi Sankyo
2025-09-29 – 2025-11-24 · Healthy Subjects
What this study did
NCT06547359 · NewAmsterdam Pharma
2024-10-01 – 2024-11-12 · Healthy Volunteers
What this study did
NCT06050291 · NewAmsterdam Pharma
2024-01-20 – 2024-04-07 · Healthy Volunteer Study
What this study did
NCT05381870 · The Affiliated Hospital of Qingdao University
2022-05-26 – 2022-12-30 · Pharmacokinetics, Safety
What this study did
NCT05481385 · The Affiliated Hospital of Qingdao University
2022-07-15 – 2022-12-30 · Pharmacokinetics, Safety
What this study did
NCT04814589 · Cao Yu
2021-03-13 – 2021-07-31 · Therapeutic Equivalency
What this study did
NCT04844996 · Mersin University
2019-09-01 – 2021-01-31 · Endometriosis
What this study did
NCT04895059 · Laboratorios Silanes S.A. de C.V.
2017-04-30 – 2018-01-22 · Healthy
What this study did
NCT02126137 · Pontificia Universidad Catolica de Chile
2013-10 – 2016-03 · Chronic Hepatitis C
What this study did
NCT02501200 · Chong Kun Dang Pharmaceutical
2015-08 – 2015-12 · Healthy
What this study did
NCT02461004 · Chong Kun Dang Pharmaceutical
2015-07 – 2015-10 · Healthy
What this study did
NCT02289430 · NVP Healthcare
2014-12 – 2015-02 · Healthy
What this study did
NCT02730689 · Alvogen Korea
2014-12 – 2015-01 · Healthy Volunteers
What this study did
NCT02127320 · Hanmi Pharmaceutical Company Limited
2014-06 – 2014-11 · Healthy
What this study did
NCT00772551 · St Stephens Aids Trust
2008-06 – 2008-08 · HIV
What this study did
NCT00681525 · Abbott
2008-04 – 2008-06 · Pharmacokinetics
What this study did
NCT00653276 · Organon and Co
2003-11 – 2004-01 · Cholesterol
What this study did
Phase 4 (72)
Atherosclerotic Cardiovascular Disease
NCT07871604 · Yonsei University
2026-11-10 – 2029-09-21 · Atherosclerosis Cardiovascular Disease
What this study did
NCT07799779 · Seoul National University Bundang Hospital
2026-11-30 – 2029-09 · Acute Coronary Syndromes (ACS)
What this study did
NCT07824323 · Taipei Medical University Hospital
2026-08-26 – 2028-12 · Acute Coronary Syndromes, Dyslipidemia
What this study did
NCT07839741 · Universidade do Porto
2025-06-01 – 2027-04 · Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Risk, LDL Cholesterol
What this study did
NCT07442630 · JW Pharmaceutical
2023-08-21 – 2026-11-30 · Hypercholesterolemia
What this study did
NCT07508254 · Punjab Institute of Cardology
2026-05-01 – 2026-10-31 · Acute Coronary Syndromes (ACS), Hypercholesterolemia
What this study did
NCT06789432 · Dr. Md. Alimur Reza
2025-02-01 – 2025-12 · Hyperlipidemia (E.G., Hypercholesterolemia)
What this study did
NCT06784557 · Yonsei University
2024-02-28 – 2025-10-01 · Atherosclerotic Cardiovascular Disease With Dyslipidemia
What this study did
NCT06381947 · University of Salerno
2024-05-01 – 2025-06-30 · Dyslipidemias, Statin Adverse Reaction, Cardiovascular Diseases, Lipid Metabolism Disorders
What this study did
NCT05661552 · Yonsei University
2022-12-01 – 2025-02-05 · Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
What this study did
NCT03750760 · Imperial College London
2020-01 – 2021-12 · Myocardial Infarction, Dyslipidemias
What this study did
NCT04638400 · paresh Dandona
2017-05-01 – 2021-11-01 · Inflammation, Atherosclerosis, Hypercholesterolemia
What this study did
NCT02772640 · Collegium Medicum w Bydgoszczy
2016-03 – 2020-05 · Hypercholesterolemia
What this study did
NCT02984982 · Sanofi
2016-11-15 – 2018-07-27 · Hypercholesterolemia, Acute Coronary Syndrome
What this study did
NCT03277079 · University of Roma La Sapienza
2017-10-01 – 2018-03-31 · Coronary Artery Disease
What this study did
NCT01807078 · University of Roma La Sapienza
2014-01 – 2017-12 · Coronary Artery Disease
What this study did
NCT02588235 · Xijing Hospital
2015-10 – 2017-11 · Coronary Artery Disease
What this study did
NCT01490229 · University of Roma La Sapienza
2013-01 – 2016-12 · Coronary Artery Disease
What this study did
NCT02103049 · University Medical Centre Ljubljana
2014-04 – 2015-12 · Dyslipidemia, Transplants
What this study did
NCT01068093 · Yokohama City University Medical Center
2010-10 – 2015-10 · Coronary Artery Disease
What this study did
NCT01043380 · Kumamoto University
2010-01 – 2014-09 · Hypercholesterolemia, Coronary Artery Disease
What this study did
NCT01611883 · Organon and Co
2012-07-02 – 2014-01-16 · Hypercholesterolemia
What this study did
NCT01086020 · Shanghai Jiao Tong University School of Medicine
2010-01 – 2012-12 · Coronary Artery Disease
What this study did
NCT00843661 · Ospedale di Circolo - Fondazione Macchi
2009-03 – 2012-07 · HIV, Hyperlipidemia, HIV Infections
What this study did
NCT00687076 · Baylor College of Medicine
2004-04 – 2010-12 · Peripheral Arterial Disease
What this study did
NCT00738985 · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
2009-11 – 2010-09 · Cardiovascular Diseases, Hyperlipidemia
What this study did
NCT01384058 · University Hospital Freiburg
2007-11 – 2010-06 · Diabetes Mellitus Type 2, Hypercholesterolemia
What this study did
NCT00481351 · University of Sao Paulo
2007-06 – 2010-01 · Coronary Heart Disease
What this study did
NCT00397657 · Walter Reed Army Medical Center
2006-11 – 2009-10 · Atherosclerosis
What this study did
NCT01008345 · Hotel Dieu de France Hospital
2008-09 – 2009-06 · Coronary Artery Disease, Diabetes
What this study did
NCT00701727 · Radiant Research
2008-06 – 2009-03 · Hypercholesterolemia
What this study did
NCT00794677 · UCSF Benioff Children's Hospital Oakland
2006-06 – 2008-09 · Hypercholesterolemia
What this study did
NCT00753883 · Merck Sharp & Dohme LLC
2006-07 – 2008-05 · Hyperlipidemia
What this study did
NCT00433823 · Abant Izzet Baysal University
2007-01 – 2008-01 · Coronary Heart Disease, Diabetes Mellitus, Non-Coronary Atherosclerotic Disease, Hypercholesterolemia
What this study did
NCT00203476 · Tuscaloosa Research & Education Advancement Corporation
2005-05 – 2008-01 · Hyperlipidemia, Hypercholesterolemia
What this study did
NCT00166504 · Organon and Co
2005-10 – 2007-10 · Hypercholesterolemia
What this study did
NCT00814723 · Medical University of Graz
2005-09 – 2007-09 · Hypercholesterolemia
What this study did
NCT00157924 · Organon and Co
2005-11 – 2007-09 · Hypercholesterolemia
What this study did
NCT00466401 · Ziv Hospital
2005-02 – 2007-08 · Hypercholesterolemia
What this study did
NCT00166530 · Organon and Co
2005-11 – 2007-02 · Atherosclerosis
What this study did
NCT00319449 · Organon and Co
2005-09 – 2006-10 · Hypercholesterolemia, Coronary Arteriosclerosis
What this study did
NCT00202904 · Organon and Co
2005-05 – 2006-10 · Hypercholesterolemia, Coronary Heart Disease
What this study did
NCT00651014 · Organon and Co
2004-01 – 2006-06 · Hypercholesterolemia, Atherosclerosis
What this study did
NCT00185107 · Daiichi Sankyo
2005-03 – 2005-10 · Hypercholesterolemia
What this study did
NCT00079638 · Kos Pharmaceuticals
2004-04 – 2005-05 · Dyslipidemia, Coronary Heart Disease, Atherosclerosis, Stroke, Diabetes
What this study did
NCT00651963 · Organon and Co
2004-09 – 2005-03 · Lipid Metabolism Disorder
What this study did
NCT00650663 · Organon and Co
2003-10-01 – 2004-09-01 · Hypercholesterolemia, Atherosclerosis
What this study did
NCT00653835 · Organon and Co
2003-09-01 – 2004-08-01 · Hypercholesterolaemia, Atherosclerosis
What this study did
Early phase / not applicable (21)
Atherosclerotic Cardiovascular Disease
NCT07626840 · Samsung Medical Center
2026-06-01 – 2031-12-31 · Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
What this study did
NCT05782777 · Yonsei University
2023-04-07 – 2027-12 · Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation
What this study did
NCT04701242 · Cairo University
2021-03-24 – 2026-12 · Acute Myocardial Infarction, Dyslipidemias
What this study did
NCT00679237 · Sorlandet Hospital HF
2007-09 – 2019-12 · Coronary Heart Disease
What this study did
NCT02942602 · Yonsei University
2014-04-03 – 2016-05-23 · Hyperlipidemia
What this study did
NCT00955227 · University of Manitoba
2009-07 – 2015-12 · Hypercholesterolemia, Hyperlipidemia
What this study did
NCT00908011 · University of British Columbia
2009-06 – 2015-01 · Hypercholesterolemia, HIV Infections
What this study did
NCT00879710 · Medical College of Wisconsin
2008-08 – 2013-07 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypercholesterolemia
What this study did
NCT02304926 · Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
2009-01 – 2011-12 · Dyslipidemia
What this study did
NCT00725829 · Jagiellonian University
2008-06 – 2009-12 · Acute Coronary Syndrome
What this study did
NCT00587678 · University of Virginia
2006-01 – 2009-10 · Peripheral Artery Disease
What this study did
NCT00485121 · Canadian Collaborative Research Network
2007-04 – 2009-04 · Metabolic Syndrome, Obesity, Coronary Artery Disease
What this study did
NCT00762229 · Bronx VA Medical Center
2007-07 – 2008-09 · Hypercholesterolemia
What this study did
NCT00475826 · University of Sao Paulo
started 2007-04 · Heterozigous Familial Hypercholesterolemia
What this study did
NCT01103648 · Federal University of São Paulo
2005-06 – 2007-11 · Prediabetes, Hypercholesterolemia, Inflammation, Cardiovascular Risk
What this study did
NCT00099684 · National Institute of Allergy and Infectious Diseases (NIAID)
2005-11 – 2007-05 · HIV Infections
What this study did
Other / comorbidity
NCT06649240 · Seoul National University Hospital
2024-10-04 – 2030-09 · Ischemic Stroke, Small Vessel Cerebrovascular Disease, Cholesterol, LDL, Secondary Prevention, Cardiovascular Diseases
What this study did
NCT04900155 · Penza State University
2020-11-20 – 2024-12 · STEMI, Covid19, NSTEMI
What this study did
NCT01584206 · University of Manitoba
2012-04 – 2016-12 · Sitosterolemia
What this study did
NCT01424891 · Heidelberg University
2004-04 – 2011-08 · Type 2 Diabetes, Inflammation
What this study did
NCT00634140 · Indiana University
2009-08 – 2009-08 · Chronic Acalculous Cholecystitis
What this study did
Used as active comparator (40)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (22)
Atherosclerotic Cardiovascular Disease
NCT06005597 · NewAmsterdam Pharma
2024-03-01 – 2024-10-16 · Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
What this study did
NCT05930028 · Boryung Pharmaceutical Co., Ltd
2023-07-13 – 2024-09-05 · Essential Hypertension, Primary Hypercholesterolemia
What this study did
NCT05763875 · Novartis Pharmaceuticals
2023-03-15 – 2024-06-20 · Hypercholesterolemia
What this study did
NCT04643093 · Orient Pharma Co., Ltd.
2020-08-01 – 2021-10-05 · Primary Hypercholesterolemia, Mixed Dyslipidemias
What this study did
NCT02715726 · Sanofi
2016-07-27 – 2018-08-06 · Hypercholesterolemia
What this study did
NCT02634580 · Amgen
2016-02-27 – 2018-05-26 · Hypercholesterolemia
What this study did
NCT01984424 · Amgen
2013-12-10 – 2017-11-21 · Hyperlipidemia
What this study did
NCT02227784 · Eli Lilly and Company
2014-10 – 2015-12 · Hyperlipidemia
What this study did
NCT02260648 · Eli Lilly and Company
2015-01 – 2015-11 · Hypercholesterolemia
What this study did
NCT01730053 · Regeneron Pharmaceuticals
2012-11-30 – 2014-05-31 · Hypercholesterolemia
What this study did
NCT01730040 · Regeneron Pharmaceuticals
2012-10 – 2014-05 · Hypercholesterolemia
What this study did
NCT01763866 · Amgen
2013-01-15 – 2013-12-04 · Hyperlipidemia
What this study did
NCT01763905 · Amgen
2013-01-24 – 2013-11-19 · Hyperlipidemia
What this study did
NCT01763827 · Amgen
2013-01-21 – 2013-10-29 · Hyperlipidemia
What this study did
NCT01644474 · Sanofi
2012-07 – 2013-07 · Hypercholesterolemia
What this study did
NCT00268697 · Takeda
2005-10 – 2007-01 · Hypercholesterolemia
What this study did
NCT00650819 · Organon and Co
2004-06-01 – 2005-02-01 · Hypercholesterolemia
What this study did
Other / comorbidity
Phase 2 (6)
Atherosclerotic Cardiovascular Disease
NCT05795517 · Haisco Pharmaceutical Group Co., Ltd.
2023-04-26 – 2024-03-01 · Hypercholesterolemia
What this study did
NCT03531905 · Esperion Therapeutics, Inc.
2018-05-09 – 2019-06-18 · Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia
What this study did
NCT01941836 · Esperion Therapeutics, Inc.
2013-09 – 2014-11 · Hypercholesterolemia
What this study did
NCT01375764 · Amgen
2011-07-28 – 2012-05-08 · Hyperlipidemia
What this study did
NCT00440154 · Sanofi
2007-02 – 2007-10 · Hypercholesterolemia
What this study did
Phase 1 (2)
Atherosclerotic Cardiovascular Disease
NCT00621699 · University Medicine Greifswald
2007-09 – 2007-11 · Pharmacokinetics, Drug Interactions, Hypercholesterolemia, Immunosuppression
What this study did
NCT00621101 · University Medicine Greifswald
2007-04 – 2007-06 · Pharmacokinetics, Drug Interactions, Hypercholesterolemia, Immunosuppression
What this study did
Phase 4 (6)
Atherosclerotic Cardiovascular Disease
NCT05365438 · Seoul National University Bundang Hospital
2022-10-01 – 2026-12-31 · Dyslipidemias, Atherosclerosis, Diabetes Mellitus, Type 2
What this study did
NCT00972829 · Bronx VA Medical Center
2009-09 – 2011-03 · Hypercholesterolemia
What this study did
NCT00651378 · Organon and Co
2004-09-01 – 2005-06-01 · Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease
What this study did
Other / comorbidity
NCT05613400 · The University of Hong Kong
2022-04-13 – 2025-06-30 · Diabetes Mellitus, Type 2
What this study did
NCT02682680 · LMC Diabetes & Endocrinology Ltd.
2016-01-11 – 2017-05-25 · Type 2 Diabetes Mellitus
What this study did
Early phase / not applicable (4)
Atherosclerotic Cardiovascular Disease
NCT03355027 · Cambridge University Hospitals NHS Foundation Trust
2017-11-30 – 2023-11-30 · Atherosclerosis, Cardiovascular Diseases
What this study did
NCT00548145 · Osaka University
2007-11 – 2012-03 · Alzheimer Disease, Hypercholesterolemia
What this study did
Other / comorbidity
NCT06854523 · Yun Dai Chen
2025-04-15 – 2026-12-31 · Acute Myocardial Infarction
What this study did
Studied as part of a combination product (76)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (30)
Atherosclerotic Cardiovascular Disease
NCT06646354 · Hyundai Pharm
2025-04-22 – 2028-12-31 · Hypertension, Primary Hypercholesterolaemia
What this study did
NCT07474649 · Daiichi Sankyo
2026-09-14 – 2028-10-02 · Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia
What this study did
NCT06305559 · NewAmsterdam Pharma
2024-05-16 – 2028-02 · Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic
What this study did
NCT07564726 · Celltrion Pharm, Inc.
2022-08-05 – 2024-02-13 · Hypertension, Hypercholesterolemia
What this study did
NCT04659070 · Hanlim Pharm. Co., Ltd.
2020-07-15 – 2022-05-19 · Primary Hypercholesterolemia, Hypertension
What this study did
NCT04161001 · Daewoong Pharmaceutical Co. LTD.
2019-11-20 – 2022-02-02 · Hypertension, Dyslipidemia
What this study did
NCT04158076 · Addpharma Inc.
2020-01-23 – 2021-01-14 · Hypercholesterolemia, Hypertension
What this study did
NCT03872232 · Addpharma Inc.
2019-02-26 – 2020-08-12 · Hypercholesterolemia, Hypertension
What this study did
NCT04074551 · Hanmi Pharmaceutical Company Limited
2019-07-16 – 2020-03-17 · Hypertension, Dyslipidemias
What this study did
NCT02251847 · IlDong Pharmaceutical Co Ltd
2014-07 – 2015-07 · Hypercholesterolemia
What this study did
NCT01420549 · Ache Laboratorios Farmaceuticos S.A.
2013-03 – 2014-11 · Hypercholesterolemia, Dyslipidemia
What this study did
NCT00202878 · Organon and Co
2005-10-17 – 2014-09-18 · Hypercholesterolemia, Myocardial Infarction
What this study did
NCT00461630 · University of Oxford
2007-01 – 2012-10 · Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus, Coronary Heart Disease
What this study did
NCT00782184 · Organon and Co
2008-11 – 2010-09 · Hypercholesterolemia
What this study did
NCT00653523 · Organon and Co
2007-12-01 – 2009-06-01 · Hypercholesterolemia
What this study did
NCT00409773 · Organon and Co
2007-01 – 2008-07 · Hypercholesterolemia, Metabolic Syndrome
What this study did
NCT00462748 · Organon and Co
2007-03 – 2008-06 · Hypercholesterolemia
What this study did
NCT00271817 · Organon and Co
2005-12 – 2008-02 · Hypercholesterolemia
What this study did
NCT00349284 · Solvay Pharmaceuticals
started 2005-01 · Hyperlipidemia Combined
What this study did
NCT00129402 · Organon and Co
2005-08 – 2007-06 · Hypercholesterolemia
What this study did
NCT00423488 · Organon and Co
2005-07-12 – 2007-02-16 · Hypercholesterolemia, Diabetes Mellitus, Type 2, Coronary Disease
What this study did
NCT00267267 · Pfizer
2006-01 – 2007-01 · Hyperlipidemia, Dyslipidemia
What this study did
NCT00413972 · Organon and Co
2006-04 – 2006-11 · Hypercholesterolemia
What this study did
Other / comorbidity
NCT07219602 · NewAmsterdam Pharma
2025-12-11 – 2028-06 · Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
What this study did
NCT06317051 · Kirby Institute
2024-12-16 – 2027-12 · HIV Infections, Weight Gain
What this study did
NCT00862251 · Organon and Co
2009-04 – 2011-03 · Cardiovascular Disorder, Diabetes Mellitus
What this study did
Phase 2/3 (2)
Atherosclerotic Cardiovascular Disease
Other / comorbidity
NCT07313124 · Beni-Suef University
2024-12-15 – 2025-12-01 · Cardiovascular Diseases (CVD)
What this study did
Phase 2 (3)
Atherosclerotic Cardiovascular Disease
NCT05266586 · NewAmsterdam Pharma
2022-03-09 – 2022-09-08 · Dyslipidemias, High Cholesterol, Hypercholesterolemia
What this study did
NCT00477204 · University of Colorado, Denver
2007-05 – 2010-08 · Type 1 Diabetes Mellitus, Dyslipidemia
What this study did
Other / comorbidity
NCT02129231 · University of Guadalajara
2012-02 – 2014-04 · Oxidative Stress, Diabetic Polyneuropathy
What this study did
Phase 1 (7)
Atherosclerotic Cardiovascular Disease
NCT06578676 · Hyundai Pharm
2024-06-20 – 2024-11-30 · Type 2 Diabetes, Dyslipidemias
What this study did
NCT02548936 · Peking Union Medical College Hospital
2015-04 – 2016-12 · Atherosclerosis
What this study did
NCT02029625 · NVP Healthcare
2014-02 – 2014-03 · Dyslipidemia
What this study did
Other / comorbidity
NCT07268625 · Daiichi Sankyo
2025-12-09 – 2026-02-24 · Healthy Subjects
What this study did
NCT07201545 · Daiichi Sankyo
2025-10-07 – 2025-12-10 · Healthy Subjects
What this study did
NCT02534376 · Cedars-Sinai Medical Center
2015-09 – 2019-02-28 · Prostate Cancer
What this study did
NCT03532854 · LG Chem
2018-05-28 – 2019-01-30 · Healthy Male Volunteers
What this study did
Phase 4 (27)
Atherosclerotic Cardiovascular Disease
NCT06186037 · Saint Vincent's Hospital, Korea
2024-02-01 – 2029-02-28 · Coronary Artery Disease, Dyslipidemias, Primary Prevention
What this study did
NCT06767345 · Korea University Anam Hospital
2025-05-12 – 2028-06-25 · Coronary Artery Disease, Atherosclerosis of Coronary Artery, Plaque, Atherosclerotic
What this study did
NCT03169985 · Samsung Medical Center
2017-07-12 – 2027-01-28 · Coronary Artery Disease
What this study did
NCT07255820 · Bahria University
2026-01-01 – 2026-06-30 · Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol
What this study did
NCT04700436 · Seoul National University Hospital
2020-01-03 – 2024-02-13 · Endocrine System Diseases, Nutritional and Metabolic Diseases, Diabetes Mellitus, Type 2, Dyslipidemias
What this study did
NCT05263778 · Kaiser Permanente
2022-03 – 2023-12 · Cardiovascular Diseases, NSTEMI, STEMI
What this study did
NCT04826354 · Korea University Anam Hospital
2021-08-11 – 2023-06-28 · Atheroscleroses, Coronary
What this study did
NCT03993236 · Keun-Sik Hong
2019-09-09 – 2021-09-27 · Stroke, Ischemic
What this study did
NCT03847506 · HK inno.N Corporation
2018-07-05 – 2020-12-02 · Hypertension, Hyperlipidemia
What this study did
NCT03543774 · Hue University of Medicine and Pharmacy
2018-06-15 – 2020-10-15 · Hypercholesterolemia, Chronic Kidney Diseases
What this study did
NCT03217409 · Yuhan Corporation
2017-08-10 – 2019-05-23 · Diabetes Mellitus and Hypercholesterolemia
What this study did
NCT00932620 · University of Ioannina
2009-06 – 2010-04 · Hypercholesterolemia
What this study did
NCT00654628 · Organon and Co
2007-08-01 – 2009-07-01 · Hypercholesterolemia
What this study did
NCT00442897 · Organon and Co
2006-09 – 2008-10 · Hypercholesterolemia
What this study did
NCT00423579 · Organon and Co
2006-07-01 – 2008-03-01 · Hypercholesterolemia, Coronary Disease
What this study did
NCT00560170 · National Cheng-Kung University Hospital
2007-09 – 2008-02 · Atherosclerosis
What this study did
NCT00652327 · Organon and Co
2005-12 – 2007-07 · Hypercholesterolemia
What this study did
NCT00385658 · Novartis
2006-08 – 2007-03 · Dyslipidemia
What this study did
NCT00189085 · UMC Utrecht
2004-12 – 2005-07 · Metabolic Syndrome
What this study did
Other / comorbidity
NCT04499859 · Kiyuk Chang, MD,PhD
2020-10-01 – 2027-08-30 · Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity
What this study did
NCT00819403 · University of Maryland, Baltimore
2009-01 – 2011-11 · Metabolic Syndrome
What this study did
NCT01185236 · Seoul National University Hospital
2010-09 – 2011-08 · Type 2 Diabetes Mellitus Without Insulin Treatment
What this study did
NCT00905905 · Brasilia Heart Study Group
2009-05 – 2010-01 · Myocardial Infarction
What this study did
NCT00738296 · Hospital Universitario 12 de Octubre
2005-04 – 2005-12 · Cardiovascular Diseases
What this study did
Early phase / not applicable (7)
Atherosclerotic Cardiovascular Disease
NCT06293417 · Korea University Anam Hospital
2024-03-01 – 2027-02-01 · T2DM (Type 2 Diabetes Mellitus), Dyslipidemias
What this study did
NCT04626973 · Yonsei University
2021-01-15 – 2025-09-24 · Atherosclerotic Cardiovascular Disease
What this study did
NCT03771053 · Chinese PLA General Hospital
2018-01-01 – 2019-12-31 · Coronary Heart Disease
What this study did
Other / comorbidity
NCT01241097 · Federal University of Bahia
2010-03 – 2011-12 · Endothelial Function
What this study did
NCT00474123 · University of Sao Paulo
2006-01 – 2009-08 · Stable Angina
What this study did
NCT00461968 · University of Texas Southwestern Medical Center
2005-02 – 2007-04 · Cholesterol, LDL
What this study did
Appears in other studies (13)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (3)
Atherosclerotic Cardiovascular Disease
NCT03001076 · Esperion Therapeutics, Inc.
2016-11-29 – 2018-02-12 · Hypercholesterolemia, Atherosclerosis, Statin Adverse Reaction
What this study did
NCT01516879 · Amgen
2012-01-05 – 2013-10-14 · Hypercholesterolemia
What this study did
Other / comorbidity
NCT04968509 · Beijing Anzhen Hospital
2024-03-22 – 2028-01 · Aortic Stenosis
What this study did
Phase 2 (4)
Atherosclerotic Cardiovascular Disease
NCT04173793 · Akeso
2019-11-18 – 2022-09-26 · Heterozygous Familial Hypercholesterolemia
What this study did
NCT04358432 · Akeso
2020-05-13 – 2021-02-25 · Hypercholesterolemia
What this study did
NCT01890967 · Eli Lilly and Company
2013-06 – 2014-06 · Hypercholesterolemia
What this study did
Homozygous Familial Hypercholesterolemia
NCT03933293 · Akeso
2019-05-13 – 2021-03-15 · Homozygous Familial Hypercholesterolemia
What this study did
Phase 1 (1)
Other / comorbidity
NCT02547402 · Complexa, Inc.
2015-12 – 2016-02 · Acute Kidney Injury
What this study did
Phase 4 (2)
Atherosclerotic Cardiovascular Disease
NCT04659525 · Policlinico Casilino ASL RMB
2020-11-01 – 2021-12-30 · Hypercholesterolemia, CKD Stage 5, Chronic Kidney Disease Requiring Chronic Dialysis
What this study did
NCT04397653 · Policlinico Casilino ASL RMB
2020-05-04 – 2020-12-14 · Hypercholesterolemia, Chronic Kidney Disease Requiring Chronic Dialysis
What this study did
Early phase / not applicable (3)
Atherosclerotic Cardiovascular Disease
NCT07359105 · Sin Gon Kim
2026-03-09 – 2029-12-31 · Dyslipidemia Associated With Type II Diabetes Mellitus
What this study did
NCT05587621 · Jena University Hospital
2024-04-01 – 2026-12-31 · ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction, LDL-cholesterol
What this study did
Other / comorbidity
NCT07704918 · University of Colorado, Denver
2026-10-19 – 2028-12 · Melanoma
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Atherosclerotic Cardiovascular Disease: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ezetimibe (Zetia): this drugPhase 3Small moleculeNPC1L1, Dietary Cholesterol Absorption InhibitorReliable signal
NCT00092586: Percent change in LDL-C: ezetimibe+statin -25.8% vs placebo+statin -2.7%; treatment difference -23.1 percentage points (P<.001)
NCT03867318: Proportion achieving LDL-C goal <=100 mg/dL at Week 14: 22% (ezetimibe 10mg + atorvastatin, n=305) vs 7% (atorvastatin dose-titration alone, n=316); P<.01
Alirocumab (Praluent)ApprovedMonoclonal antibodyPCSK9Weak signal
NCT03510884: DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7)
NCT01709500: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis (From Baseline to Week 52): Alirocumab 75 mg/up to 150 mg -48.7 percent change (Standard Error 1.9) vs Placebo 2.8 percent change (Standard Error 2.8)
Bempedoic Acid (Nexletol)ApprovedSmall moleculeATP citrate lyasePartial signal
NCT02991118: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid -15.07 percent change (Standard Error 1.073) vs Placebo 2.35 percent change (Standard Error 1.446)
NCT02988115: Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline; Week 12): Bempedoic Acid -22.58% (Standard Error 1.29) vs Placebo -1.17% (Standard Error 1.421)
Bempedoic Acid / Ezetimibe (Nexlizet)ApprovedSmall moleculeATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Partial signal
NCT03337308: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC -36.2% (Standard Error 2.56) vs Bempedoic Acid 180 mg -17.2% (Standard Error 2.52) vs Ezetimibe 10 mg -23.2% (Standard Error 2.18) vs Placebo 1.8% (Standard Error 3.49)
Cangrelor (Kengreal)ApprovedSmall moleculeP2Y12 receptorPartial signal
NCT00385138: Death, MI or ischemia-driven revascularization at 48 h: 7.0% cangrelor (185/2654) vs 8.0% placebo (210/2641); OR 0.87, 95% CI 0.71 to 1.07; P=0.17. Both arms received clopidogrel 600 mg (CHAMPION PLATFORM, NEJM 2009). missed
Colchicine (cardiovascular) (Lodoco)ApprovedSmall moleculeMicrotubule/inflammasome (tubulin)not yet gradedNo reviewed efficacy summary in this indication
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
Evolocumab (Repatha)ApprovedMonoclonal antibodyPCSK9Partial signal
NCT02392559: Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08)
NCT02207634: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score (Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).): Evolocumab 0.1134 Z score (95% CI 0.0449 to 0.182) vs Placebo 0.1206 Z score (95% CI 0.0535 to 0.1877)
Ezetimibe / Simvastatin (Vytorin)ApprovedSmall moleculeHMG-CoA reductase / NPC1L1Reliable signal
NCT00202878: Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81)
NCT00110435: Percent reduction in LDL-C from baseline at 6 weeks: ezetimibe/simvastatin 10/20mg -53.6% vs atorvastatin 10mg -38.3% (P<.001) and vs atorvastatin 20mg -44.6% (P<.001); ezetimibe/simvastatin 10/40mg -57.6% vs atorvastatin 40mg -50.9% (P<.001). Primary endpoint (percent change from baseline in LDL-C) significantly favored ezetimibe/simvastatin at both dose comparisons.
Icosapent Ethyl (Vascepa)ApprovedSmall moleculeOmega-3 fatty acid (EPA)Reliable signal
NCT01492361: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. (Total follow-up time of up to approximately 6 years.): AMR101 705/4089 vs Placebo 901/4090
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT04560998: Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Wegovy)ApprovedPeptideGLP-1 receptorReliable signal
NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801
Ticagrelor (Brilinta)ApprovedSmall moleculeP2Y12 receptorPartial signalFeatured results are non-efficacy only in this race
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
AG2304Phase 3Small moleculeHMG-CoA reductase / NPC1L1Partial signalNo reviewed efficacy summary in this indication
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet graded
NCT01263925: ClinicalTrials.gov results section for NCT01263925 ('Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication', UCB Pharma, Phase 3, enrollment 561/541 FAS, completed April 2011 -- matches this record exactly). Primary outcome: pain-free walking-distance ratio vs active comparator (pentoxifylline) across three periods; both treatments produced similar improvements with no clear superiority of either. phase 3 result · pivotal pending
Amlodipine / Valsartan / Atorvastatin (CJ-30061)Phase 3Small moleculeAngiotensin II receptor / Calcium channel / HMG-CoA reductasePartial signalNo reviewed efficacy summary in this indication
Beperminogene Perplasmid (HGF Plasmid) (Collategene)Phase 3Gene therapy / editingHGF (hepatocyte growth factor), Hepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
Cilostazol / Rosuvastatin (UI022 / UI023)Phase 3Small moleculePDE3 (phosphodiesterase 3) and HMG-CoA reductaseReliable signal
NCT07600385: KPAQ summary score change (FAS, n=257): test group 15.41 points (SD 14.18) vs control group 10.27 points (SD 14.70); between-group difference 5.14 points (P=0.004), test group superior.
DalcetrapibPhase 3Small moleculeCETPPartial signal
NCT00658515: Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). missed
NCT01059682: Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS. (24 months): Dalcetrapib 0.6% (Standard Deviation 3.69) vs Placebo 0.5% (Standard Deviation 2.01)
Dapagliflozin (Farxiga / Forxiga)Phase 3Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
DWC202206 + DWC202207Phase 3Small molecule—Partial signalNo reviewed efficacy summary in this indication
EbronucimabPhase 3Monoclonal antibodyPCSK9Partial signal
NCT05255094: LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001).
Enlicitide (Lipfendra)Phase 3PeptidePCSK9Reliable signal
NCT05952856: Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001).
NCT05952869: Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24): Enlicitide Decanoate -58.2% (Standard Deviation 28) vs Placebo 2.6% (Standard Deviation 23.6)
Fimasartan / Atorvastatin / Ezetimibe (BR1017)Phase 3Small moleculeAT1 receptor; NPC1L1; HMG-CoA reductasePartial signal
NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025).
HyzetimibePhase 3Small moleculeNPC1L1Partial signal
NCT03433196: LDL-C percent change from baseline (primary endpoint, week 12): -16.39% (95% CI -19.04 to -13.74) with hyzetimibe (HS-25, referred to in this paper as hybutimibe) + atorvastatin vs -6.75% (95% CI -9.48 to -4.02) with atorvastatin alone, P<0.0001
NCT03413462: 第12周试验组LDL-C较基线的变化率为(-10.23±13.58)%,显著优于对照组(4.34±15.88)%。
Inclisiran (Leqvio)Phase 3RNA / oligonucleotidePCSK9Partial signal
NCT04652726: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78)
NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52)
LaroprovstatPhase 3Small moleculePCSK9Reliable signal
NCT06173570: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo)
Laroprovstat / RosuvastatinPhase 3Small moleculePCSK9 (laroprovstat component) + HMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
LepodisiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT05565742: Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo)
Lerodalcibep (Lerochol)Phase 3Protein / enzyme therapeuticPCSK9Reliable signal
NCT04797104: LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001)
NCT05004675: LDL-C change from baseline at Day 270 (mITT): -53% with lerodalcibep vs -45.3% with inclisiran (P=0.0319); per-protocol: -55.4% vs -45.4% (P=0.005)
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
MuvalaplinPhase 3Small moleculeApolipoprotein(a) [apo(a)] kringle domain / apo(a)-apoB100 interactionPartial signal
NCT05563246: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay (Baseline, Week 12): 10 mg LY3473329 -47.35% ± 4.811 vs 60 mg LY3473329 -81.57% ± 1.230 vs 240 mg LY3473329 -85.71% ± 0.927 vs Placebo 0.48% ± 6.382; p=<.001 (10 mg LY3473329 vs Placebo), p=<.001 (60 mg LY3473329 vs Placebo), p=<.001 (240 mg LY3473329 vs Placebo)
NL003Phase 3Gene therapy / editingHepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPPartial signal
NCT05142722: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571)
NCT05425745: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10 mg -36.05% (Standard Error 1.769) vs Placebo 0.25% (Standard Error 2.48)
Obicetrapib / Ezetimibe (Evlarco)Phase 3Small moleculeCETP, NPC1L1Partial signal
NCT06005597: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564)
OlpasiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT04270760: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Group 1: Olpasiran 10 mg Q12W -66.91% ± 1.78 vs Group 2: Olpasiran 75 mg Q12W -93.78% ± 1.78 vs Group 3: Olpasiran 225 mg Q12W -97.53% ± 1.82 vs Group 4: Olpasiran 225 mg Q24W -96.89% ± 1.85 vs Group 5: Placebo Q12W 3.60% ± 1.89; p=<0.001 (Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W), p=< 0.001 (Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W)
Ongericimab (Junshida)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT05325203: Percent change in LDL-C from baseline to week 24 (JS002-005/NCT05325203, HeFH, 135 patients): ongericimab 150mg Q2W -69.4% vs placebo (p<0.0001); ongericimab 450mg Q4W -80.6% vs placebo (p<0.0001)
NCT04781114: LDL-C percentage change from baseline to week 24 vs placebo: 150 mg Q2W -67.7% (95% CI -72.5% to -63.0%; P<0.0001); 300 mg Q4W -61.2% (95% CI -67.1% to -55.2%; P<0.0001).
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
PelacarsenPhase 3RNA / oligonucleotideApolipoprotein(a) mRNAPartial signal
NCT05305664: Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule (Up to Week 52): Pelacarsen (TQJ230) 0.16 Apheresis sessions received per week (IQR 0.04 to 0.25) vs Placebo 0.93 Apheresis sessions received per week (IQR 0.9 to 1)
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaPartial signalNo reviewed efficacy summary in this indication
PMR (cilostazol ER)Phase 3Small moleculePhosphodiesterase 3 (PDE3)Weak signalNo reviewed efficacy summary in this indication
PravafenixPhase 3Small moleculeHMG-CoA reductase / PPAR-alphaPartial signalNo reviewed efficacy summary in this indication
QLC7401Phase 3RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
RanolazinePhase 3Small moleculeCardiac late sodium current (late INa, Nav1.5)Partial signal
NCT00099788: The primary end point occurred in 696 patients (21.8%) in the ranolazine group and 753 patients (23.5%) in the placebo group (hazard ratio 0.92). missed
NCT01562041: Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index (Baseline up to Day 15): Ranolazine 500 mg — Test 1: 3.211 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.6553); Test 2: 2.822 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0289); Test 3: 3.228 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.891); Test 4: 2.502 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.8884); Change From Baseline in Maximum ST/Heart Rate Index: -0.605 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0482)
RecaticimabPhase 3Monoclonal antibodyPCSK9Reliable signal
NCT04844125: Change in LDL-C from baseline at Week 12: -54.4% recaticimab vs -4.5% placebo; treatment difference -49.8 percentage points (95% CI -55.8 to -43.9), P<0.0001
NCT04849000: LDL-C reduction vs placebo at the primary endpoint timepoint: 150 mg Q4W -49.6% (95% CI 44.2-54.9%); 300 mg Q8W -52.8% (95% CI 48.3-57.2%); 450 mg Q12W -45.0% (95% CI 41.0-49.0%); P<0.0001 for all comparisons.
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
SAL003Phase 3Monoclonal antibodyPCSK9Partial signalNo reviewed efficacy summary in this indication
Sarpogrelate (Anplag)Phase 3Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
SumecigrelPhase 3Small moleculeP2Y12 platelet receptorPartial signal
NCT03599284: Primary, inhibition of ADP-induced platelet aggregation (%IPA) at day 28: vicagrel 20/5 mg 30.19%, 24/6 mg 35.02%, 30/7.5 mg 45.61%, clopidogrel 32.55%; the paper reports these as comparable across all groups (P=0.0694) and sets no non-inferiority margin.
SYH2053Phase 3RNA / oligonucleotidePCSK9Partial signalNo reviewed efficacy summary in this indication
Tafolecimab (Sintbilo)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT04289285: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001
NCT04709536: Percent change in LDL-C from baseline to Week 12: tafolecimab -68.9% (SE 1.4%) vs placebo -5.8% (SE 1.8%); treatment difference -63.0% (95% CI -66.5% to -59.6%, P<0.0001)
ZiltivekimabPhase 3Monoclonal antibodyInterleukin-6Partial signal
NCT05021835: 3-point MACE (CV death, non-fatal MI, non-fatal stroke): HR 0.99 (95% CI 0.88-1.11) for ziltivekimab vs placebo. missed
NeovasculgenPhase 2/3Gene therapy / editingVEGF165 gene therapy (angiogenic plasmid)Partial signal
NCT03068585: Pain-free walking distance increased in the pCMV-vegf165 (Neovasculgen) treatment group by 110.4% at 6 months, versus no positive results in the standard-treatment control group
ABP-745Phase 2Small moleculeNLRP3 inflammasomenot yet gradedNo reviewed efficacy summary in this indication
ACP-01Phase 2Biologic (subtype unspecified)Autologous angiogenic cell precursor (ACP) therapyPartial signal
NCT02551679: Primary composite (de-novo gangrene, doubling of wound size, major amputation or death within 1 year): 12 of 46 participants on ACP-01 vs 3 of 21 on placebo, hazard ratio 2.046 (95% CI 0.577 to 7.255), p=0.258 (CT.gov posted results). missed
APACPhase 2PeptideVascular injury site glycocalyx / coagulation cascadenot yet gradedNo reviewed efficacy summary in this indication
BW-20829Phase 2RNA / oligonucleotideLipoprotein(a) [Lp(a)] production pathwaynot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 61 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(14 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Zetia (Ezetimibe) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Early phase / not applicableAtherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2026-12 · NCT04701242 · CT.gov ↗
What to watch
2027 (3)
January 2027 (1)
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-01 · NCT07839741 · CT.gov ↗
What to watch
July 2027 (1)
Phase 4Type 1 DiabetesRecruiting
Est. primary completion 2027-07-01 · NCT05641753 · CT.gov ↗
What to watch
December 2027 (1)
Early phase / not applicableAtherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-12 · NCT05782777 · CT.gov ↗
What to watch
2028 (5)
February 2028 (1)
Phase 2Prostate CancerRecruiting
Est. primary completion 2028-02-29 · NCT06437574 · CT.gov ↗
What to watch
March 2028 (1)
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2028-03 · NCT07824323 · CT.gov ↗
What to watch
June 2028 (2)
Phase 4Atrial Fibrillation, Post-Catheter Ablation Atrial Arrhythmia RecurrenceNot yet recruiting
Est. primary completion 2028-06-01 · NCT07752758 · CT.gov ↗
What to watch
Early phase / not applicableAtherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2028-06-01 · NCT07626840 · CT.gov ↗
What to watch
September 2028 (1)
Phase 4Intracranial Arteriosclerosis, Cognitive ImpairmentNot yet recruiting
Est. primary completion 2028-09-30 · NCT07605130 · CT.gov ↗
What to watch
2029 (3)
July 2029 (1)
Phase 2Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2029-07-31 · NCT07307989 · CT.gov ↗
What to watch
September 2029 (2)
Phase 4Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2029-09 · NCT07799779 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2029-09-21 · NCT07871604 · CT.gov ↗
What to watch
2030 (1)
September 2030 (1)
Early phase / not applicableIschemic Stroke, Small Vessel Cerebrovascular Disease, Cholesterol, LDL, Secondary Prevention, Cardiovascular DiseasesRecruiting
Est. primary completion 2030-09 · NCT06649240 · CT.gov ↗
What to watch
2032 (1)
June 2032 (1)
Phase 4Primary Prevention, Vascular CalcificationRecruiting
Est. primary completion 2032-06-30 · NCT06722521 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 November 2024Topline resultTANDEM Phase 3 topline: obicetrapib/ezetimibe fixed-dose combination